The role of CCK2 receptors in the homeostasis of the opioid system

Drugs of Today

Volumn 39, Issue 11, 2003, Pages 897-908

  Noble, Florence ^a,b   Roques, Bernard P ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DELTA OPIATE RECEPTOR; ENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; NALOXONE; NEUROPEPTIDE; OPIATE; OPIATE RECEPTOR; CHOLECYSTOKININ RECEPTOR; OPIATE PEPTIDE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTINOCICEPTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG POTENTIATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OPIATE ADDICTION; PAIN; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; ANIMAL; DRUG EFFECT; HOMEOSTASIS; METABOLISM; PHYSIOLOGY;

ANIMALS; CHOLECYSTOKININ; HOMEOSTASIS; OPIOID PEPTIDES; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, OPIOID;

EID: 0345825946     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.11.799467     Document Type: Review

References (92)

1. Vanderhaeghen, J.J., Signeau, J.C., Gepts, W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature (Lond.) 1975, 257: 604-5.
2. Moran, T.H., Robinson, P.H., Goldrich, M.S., McHugh, P.R. Two brain cholecystokinin receptors: Implications for behavioral actions. Brain Res 1986, 362: 175-9.
3. Wank, S.A., Pisegna, J.R., De Weerth, A. Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. Proc Natl Acad Sci USA 1992, 89: 8691-5.
4. Kopin, A.S., Lee, Y.M., McBride, E.W. et al. Expression, cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 1992, 89: 3605-9.
5. Lee, Y.M., Beinborn, M., McBride, E.W., Lu, M., Kolakowski, L.F., Kopin, A.S. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem 1993, 268: 8164-9.
6. Stengaard-Pedersen, K., Larsson, L.I. Localization and opiate receptor binding of enkephalin, CCK and ACTH/beta-endorphin in the rat central nervous system. Peptides 1981, 2 (Suppl. 1): 3-19.
7. Gall, C., Lauterborn, J., Burks, D., Seroogy, K. Co-localization of enkephalins and cholecystokinin in discrete areas of rat brain. Brain Res 1987, 403: 403-8.
8. Skinner, K., Basbaum, A.I., Fields, H.L. Cholecystokinin and enkephalin in brain stem pain modulating circuits. Neuroreport 1997, 8: 2995-8.
9. Zhang, X., de Araujo Lucas, G., Elde, R., Wiesenfeld-Hallin, Z., Hokfelt, T. Effect of morphine on cholecystokinin and mu-opioid receptor-like immunoreactivities in rat spinal dorsal horn neurons after peripheral axotomy and inflammation. Neuroscience 2000, 95: 197-207.
10. Watkins, L.R., Mayer, D.J. Multiple endogenous opiate and non-opiate analgesia systems: Evidence of their existence and clinical implications. Ann NY Acad Sci 1986, 467: 273-99.
11. Crawley, J.N., Corwin, R.L. Biological actions of cholecystokinin. Peptides 1994, 15: 731-55.
12. Daugé, V., Roques, B.P. Opioid and CCK systems in anxiety and reward. In: Cholecystokinin and anxiety: From neuron to behavior. J. Bradwejn, E. Vasar (Eds.). RG Landes Company: Austin 1995, 151-71.
13. Faris, P.L., Komisaruk, B.R., Watkins, L.R., Mayer, D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219: 310-2.
14. Faris, P.L., McLaughlin, C.L., Baile, C.A., Olney, J.W., Komisaruk, B.R. Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science 1984, 226: 1215-7.
15. Baber, N.S., Dourish, C.T., Hill, D.R. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 1989, 39: 307-28.
16. Fournishé-Zaluski, M.C., Coric, P., Turcaud, S. et al. Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J Med Chem 1992, 35: 2474-81.
17. Nagata, A., Ito, M., Iwata, N. et al. G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc Natl Acad Sci USA 1996, 93: 11825-30.
18. Roques, B.P., Noble, F. Association of enkephalin catabolism inhibitors and CCK-B antagonists: A potential use in the management of pain and opioid addiction. Neurochem Res 1996, 21: 1395-1409.
19. Noble, F., Soleilhac, J.M., Soroca-Lucas, E., Turcaud, S., Fournié-Zaluski, M.C., Roques, B.P. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 1992, 261: 181-90.
20. Derrien, M., Noble, F., Maldonado, R., Roques, B.P. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Neurosci Lett 1993, 160: 193-6.
21. Noble, F., Derrien, M., Roques, B.P. Modulation of opioid analgesia by CCK at the supraspinal level: Evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmcol 1993, 109: 1064-70.
22. 2 with μ and δ opioid antinociception in the rat spinal cord. Neuropeptides 1990, 16: 213-8.
23. Rattray, M., De Belleroche, J. Morphine action on cholecystokinin octapeptide release from rat periaqueductal grey slices: Sensitization by naloxone. Neuropeptides 1987, 10: 189-200.
24. Rodriguez, R.E., Sacristán, M.P. In vivo release of CCK-8 from the dorsal horn of the rat: Inhibition by DAGOL. FEBS Lett 1989, 250: 215-7.
25. Benoliel, J.J., Bourgoin, S., Mauborgne, A., Legrand, J.C., Hamon, M., Cesselin, F. Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by δ receptor stimulation. Neurosci Lett 1991, 124: 204-7.
26. Benoliel, J.J., Mauborgne, A., Bourgoin, S., Legrand, J.C., Hamon, M., Cesselin, F. Opioid control of the in vitro release of CCK-like material from the rat substantia nigra. J Neurochem 1992, 58: 916-22.
27. 3H]pBC 264, first highly potent and very selective radioligand for CCK-B receptors. Eur J Pharmacol 1989, 168: 269-70.
28. Gacel, G., Daugé, V., Breuzé, P., Delay-Goyet, P., Roques, B.P. Development of conformationally constrained linear peptides exhibiting a high affinity and pronounced selectivity for δ-opioid receptors. J Med Chem 1988, 24: 1119-24.
29. 3H]pBC264: Evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J Neurochem 1992, 59: 1805-11.
30. Gustafsson, H., Afrah, A.W., Stiller, C.O. Morphine-induced in vivo release of spinal cholecystokinin is mediated by delta-opioid receptors - Effect of peripheral axotomy. J Neurochem 2001, 78: 55-63.
31. Maldonado, R., Derrien, M., Noble, F., Roques, B.P. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. NeuroReport 1993, 4: 947-50.
32. Valverde, O., Maldonado, R., Fournié-Zaluski, M.C., Roques, B.P. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 1994, 270: 77-88.
33. Hökfelt, T., Xu, Z., Verge, V. et al. Messenger plasticity in primary sensory neurons. In: Neuropeptides, Nociception, and Pain. T. Hökfelt, H.G. Schaible and R.F. Schmidt (Eds.). Chapman and Hall: Weinheim 1994, 71-84.
34. Antunes Bras, J.M., Laporte, A.M., Benoliel, J.J. et al. Effects of peripheral axotomy on cholecystokinin neurotransmission in the rat spinal cord. J Neurochem 1999, 72: 858-67.
35. Xu, X.J., Alster, P., Wu, W.P., Hao, J.X., Wiesenfeld-Hallin, Z. Increased level of cholecystokinin in cerebrospinal fluid is associated with chronic pain-like behavior in spinally injured rats. Peptides 2001, 22: 1305-8.
36. Nichols, M.L., Bian, D., Ossipov, M.H., Lai, J., Porreca, F. Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neurophatic pain in rats. J Pharmacol Exp Ther 1995, 275: 1339-45.
37. Idänpään-Heikkilä, J.J., Perrot, S., Guilbaud, G., Kayser, V. In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK-B receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics. Eur J Pharmacol 1997, 325: 155-64.
38. Honoré, P., Buritova, J., Fournié-Zaluski, M.C., Roques, B.P., Besson, J.M. Antinociceptive effects of RB 101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a CCK-B receptor antagonist as revealed by noxiously-evoked spinal c-fos expression in the rat. J Pharmacol Exp Ther 1997, 281: 208-17.
39. Coudoré-Civiale, M.A., Courteix, C., Fialip, J., Boucher, M., Eschalier, A. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats. Pain 2000, 88: 15-22.
40. Coudoré-Civiale, M.A., Meen, M., Fournié-Zaluski, M.C., Boucher, M., Roques, B.P., Eschalier, A. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats. Br J Pharmacol 2001, 133: 179-185.
41. Xu, X.J., Elfvin, A., Hao, J.X., Fournié-Zaluski, M.C., Roques, B.P., Wiesenfeld-Hallin, Z. CI-988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level. Neuropeptides 1997, 31: 287-91.
42. McCleane, G.J. A phase I study of the cholecystokinin (CCK) B antagonist L-365,260 in human subjects taking morphine for intractable non-cancerpain. Neurosci Lett 2002, 332: 210-2.
43. Price, D.D., von der Gruen, A., Miller, J., Rafii, A., Price, C. Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist. Anesth Analg 1985, 64: 801-6.
44. Benedetti, F., Amanzio, M., Maggi, G. Potentiation of placebo analgesia by proglumide. Lancet 1995, 346: 1231.
45. Benedetti, F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996, 64: 535-43.
46. Bernstein, Z.P., Yucht, S., Battista, E., Lema, M., Spaulding, M.B. Proglumide as a morphine adjunct in cancer pain management. J Pain Symptom Manage 1998, 15: 314-20.
47. Lehmann, K.A., Schlusener, M., Arabatsis, P. Failure of proglumide, a cholecystokinin antagonist, to potentiate clinical morphine analgesia. A randomized double-blind postoperative study using patient-controlled analgesia (PCA). Anesth Analg 1989, 68: 51-6.
48. Zhou, Y., Sun, Y.H., Zhang, Z.W., Han, J.S. Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. NeuroReport 1992, 3: 1121-3.
49. Pu, S.F., Zhuang, H.X., Lu, Z.B., Wu, X.R., Han, J.S. Cholecystokinin gene expression in rat amygdaloid neurons. Normal distribution and effect of morphine tolerance. Mol Brain Res 1994, 21: 183-9.
50. Pohl, M., Collin, E., Benoliel, J.J., Bourgoin, S., Cesselin, F., Hamon, M. Cholecystokinin (CCK)-like material and CCK mRNA levels in the rat brain and spinal cord after acute or repeated morphine treatment. Neuropeptides 1992, 21: 193-200.
51. Tortorici, V., Nogueira, L., Salas, R., Vanegas, H. Involvement of local cholecystokinin in the tolerance induced by morphine microinjections into the periaqueductal gray of rats. Pain 2003, 102: 9-16.
52. Valverde, O., Blommaert, A.G.S., Fournié-Zaluski, M.C., Roques, B.P., Maldonado, R. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCK-B antagonist. Eur J Pharmacol 1995, 286: 79-93.
53. Pournaghash, S., Riley, A. Failure of cholecystokinin to precipitate withdrawal in morphine-treated rats. Pharmacol Biochem Behav 1991, 38: 479-84.
54. Maldonado, R., Valverde, O., Derrien, M., Tejedor-Real, P., Roques, B.P. Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats. Pharmacol Biochem Behav 1994, 48: 363-9.
55. Mas Nieto, M., Wilson, J., Cupo, A., Roques, B.P., Noble, F. Chronic morphine treatment modulates the extracellular levels of endogenous enkephalins in rat brain structures involved in opiate dependence: A microdialysis study. J Neurosci 2002, 22: 1034-41.
56. Panerai, A.E., Rovati, L.C., Cocco, E., Sacerdote, P., Mantegazza, P. Dissociation of tolerance and dependence to morphine: A possible role for cholecystokinin. Brain Res 1987, 410: 52-60.
57. Dourish, C.T., O'Neill, M.F., Couglan, J., Kitchener, S.J., Hawley, D., Iversen, S.D. The selective CCK-B antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in rat. Eur J Pharmacol 1990, 175: 35-44.
58. Xu, X.J., Wiesenfeld-Hallin, Z., Hughes, J., Horwell, D.C., Hökfelt, T. CI 988, a selective antagonist of cholecystokinin-B receptors, prevents morphine tolerance in rats. Br J Pharmacol 1992, 105: 591-6.
59. Zhou, Y., Sun, Y.H., Zhang, Z.W., Han, J.S. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCK-B receptor antagonist L-365,260 in rat spinal cord. Eur J Pharmacol 1993, 234: 147-54.
60. Becker, C., Pohl, M., Thiébot, M.H. et al. Delta-opioid receptor-mediated increase in cortical extracellular levels of cholecystokinin-like material by subchronic morphine in rats. Neuropharmacology 2000, 39: 161-71.
61. Belluzzi, J.D., Stein, L. Enkephalin may mediate euphoria and drive-reduction reward. Nature 1977, 266: 556-8.
62. Koob, G.F., Le Moal, M. Drug abuse: Hedonic homeostatic dysregulation. Science 1997, 278: 52-8.
63. Roques, B.P., Noble, F., Daugé, V., Fournié-Zaluski, M.C., Beaumont, A. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993, 45: 87-146.
64. Higgins, G.A., Nguyen, P., Sellers, E.M. Blockade of morphine conditioning by the CCK-A receptor antagonist devazepide. Eur J Pharmacol 1991, 197: 229-30.
65. Higgins, G.A., Nguyen, P., Sellers, E.M. Morphine place conditioning is differentially affected by CCK-A and CCK-B receptor antagonists. Brain Res 1992, 572: 208-15.
66. Noble, F., Fournié-Zaluski, M.C., Roques, B.P. Unlike morphine, the endogenous enkephalins protected by RB 101 are unable to establish a conditioned place preference in m/ce mice. Eur J Pharmacol 1993, 230: 139-49.
67. Hutcheson, D.M., Subhan, F., Pache, D.M. et al. Analgesic doses of the enkephalin degrading enzyme inhibtor RB 120 do not have discriminative stimulus properties. Eur J Pharmacol 2000, 401: 197-204.
68. Higgins, G.A., Joharchi, N., Wang, Y., Corrigall, W.A., Sellers, E.M. The CCK-A receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: Comparison with the dopamine antagonist haloperidol. Brain Res 1994, 640: 246-54.
69. Maldonado, R., Saiardi, A., Valverde, O., Samad, T.A., Roques, B.P., Borrelli, E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 1997, 388: 586-9.
70. Di Chiara, G. Drug addiction as dopamine-dependent associative learning disorder Eur J Pharmacol 1999, 375: 13-30.
71. Groenewegen, H.J., Berendse, H.W., Meredith, G.E. et al. Functional anatomy of the ventral limbic system-innervated striatum striaturn. In: The mesolimbic dopamine system: From motivation to action. P. Willner and J. Scheel-Krüger (Eds.). Wiley: New York 1991, 95-118.
72. Totterdell, S., Smith, A.D. Cholecystokinin-immunoreactive boutons in synaptic contact with hippocampal pyramidal neurons that project to the nucleus accumbens. Neuroscience 1986, 19: 181-92.
73. Crawley, J.N. Cholecystokinin-dopamine interactions. Trends Pharmacol Sci 1991, 12: 232-6.
74. Willner, P. Animal models of depression: An overview. Pharmacol Ther 1990, 45: 425-55.
75. Roques, B.P., Daugé, V., Gacel, G., Fournié-Zaluski, M.C. Selective agonists and antagonists of delta opioid receptors and inhibitors of enkephalins metabolism. Potential use in mental illness. In: Biological psychiatry, Developments in psychiatry. C. Shagass, R.C. Josiassen, W.H. Bridger, K.J. Weiss, D. Stoff and G.M. Simpon (Eds.). Elsevier: New York 1985, 287-289.
76. 1 receptor stimulation. Eur J Pharmacol 1992, 216: 157-66.
77. Smadja, C., Maldonado, R., Turcaud, S., Fournié-Zaluski, M.C., Roques, B.P. Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalins antidepressant-like effects. Psychopharmacology 1995, 128: 400-8.
78. Derrien, M., Durieux, M., Roques, B.P. Antidepressant-like effects of CCK-B antagonists in mice: Antagonism by naltrindole. Br J Pharmacol 1994, 111: 956-60.
79. Hernando, F., Fuentes, J.A., Fournié-Zaluski, M.C., Roques, B.P., Ruiz-Gayo, M. Antidepressant-like effects of CCK-B receptor antagonists: Involvement of the opioid system. Eur J Pharmacol 1996, 318: 221-9.
80. Pommier, B., Beslot, F., Simon, A. et al. Deletion of CCK2 receptor in mice results in an up-regulation of the endogenous opioid system. J Neurosci 2002, 22: 2005-11.
81. Kalivas, P.W., Taylor, S., Miller, J.S. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. I. Behavioral characterization. J Pharmacol Exp Ther 1985, 235: 537-43.
82. Calenco-Choukroun, G., Daugé, V., Gacel, G., Féger, J., Roques, B.P. Opioid delta agonists and endogenous enkephalins induce different emotional reactivity than mu agonists after injection in the rat ventral tegmental area. Psychopharmacology 1991, 103: 493-502.
83. Daugé, V., Sebret, A., Beslot, F., Matsui, T., Roques, B.P. Behavioral profile of CCK2 receptor-deficient mice. Neuropsychopharmacology 2001, 25: 690-8.
84. Veraksits, A., Runkorg, K., Kurrikoff, K. et al. Altered pain sensitivity and morphine-induced anti-nociception in mice lacking CCK2 receptors. Psychopharmacology (Berl) 2003, 166: 168-75.
85. Willer, J.C., Le Bars, D., De Broucker, T. Diffuse noxious inhibitory controls in man: Involvement of an opioidergic link. Eur J Pharmacol 1990, 182: 347-55.
86. Noble, F., Fournié-Zaluski, M.C., Roques, B.P. Paradoxical analgesia induced by low doses of naloxone is not potentiated by complete inhibition of enkephalin degradation. Neuropharmacology 1994, 33: 135-40.
87. Larcher, A., Laulin, J.P., Célèrier, E., Le Moal, M., Simonnet, G. Acute tolerance associated with a single opiate administration: Involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience 1998, 84: 583-9.
88. Célèrier, E., Laulin, J.P., Corcuff, J.B., Le Moal, M., Simonnet, G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: A sensitization process. J Neurosci 2001, 21: 4074-80.
89. Cerne, R., Jiang, M., Randic, M. Cyclic adenosine 3′5′ -monophosphate potentiates excitatory amino acid and synaptic responses of rat spinal dorsal hom neurons. Brain Res 1992, 596: 111-23.
90. Cox, B.M. Opioid receptor-G protein interactions: Acute and chronic effects of opioids. In: Handb. Exp. Pharm. Opioids I. A. Herz (Ed.). Springer-Verlag: Berlin Heidelberg 1993, 145-88.
91. Randic, M., Cheng, G., Kojic, L. Kappa-opioid receptor agonists modulate excitatory transmission in substantia gelatinosa neurons of the rat spinal cord. J. Neurosci 1995, 15: 6809-26.
92. Vanegas, H., Schaible, H.G. Prostaglandins and cycloxygenases in the spinal cord. Prog Neurobiol 2001, 64: 327-63.